pharmaceutical policy recommendations. The goal of this entity would be to generate evidence and action steps to ensure people have equitable and affordable access to prescription medications, to maximize the value of public and private pharmaceutical expenditures on health, to support novel drug development within a market-based economy, and to preserve clinician and patient choice regarding personalized treatment. An immediate priority is to examine the evidence and make recommendations regarding the need to have essential medicines with established clinical benefit from each drug class in all Tier 1 formularies and propose recommendations to reduce barriers to timely generic drug availability.
Overview
Rising healthcare costs are leading to higher out-of-pocket (OOP) expenses for patients, such that one-quarter of families report health spending imposes a significant financial burden. This burden is especially high among individuals with low and middle incomes who have chronic respiratory conditions and is magnified by the limited availability of generic medicines within many drug classes. Even when generics are available, their prices are unexpectedly high because of lack of competition. Rising medication costs increase stress and fear, and cost-related nonadherence worsens health status and leads to unnecessary hospitalizations. Other economically developed countries have taken greater steps than the United States to establish policies to protect patients from unmanageable prescription medication expenses. There is a pressing need in the United States to establish more consistent and rational pharmaceutical policies at the national level.
The current market for prescription medications is complex and contains numerous government and private entities that regulate, develop, distribute, dispense, and purchase prescription medications. Recommendations addressing affordability must acknowledge the diverse roles these entities play in making medications available to patients. The National Academies of Science, Engineering, and Medicine and others recommend important reforms based on careful and objective examination of available evidence. Given the difficulty of crafting and implementing evidence-based policies in a complex and dynamic pharmaceutical supply chain, a system is needed to monitor long-term outcomes and adapt to changing circumstances.
The following policy recommendations are designed to address the long-term challenges facing the nation as a whole, to better serve all patients in need of prescription medications, not just those with respiratory disease: 
Introduction
Prescription medication spending has garnered notable attention in the United States because rising expenditures are straining government and patient finances.
Demand for prescription medications is high, given 50% of adults have at least one chronic condition and 25% have two or more (1) . Sixty percent of the population and 90% of Medicare beneficiaries have taken at least one prescription medication in the past month (2) . Although prescription medication spending accounts for 22% of all expenditures devoted to treating individual medical conditions, it accounts for 28% among those with chronic respiratory conditions and 58% among those with asthma, a highly prevalent disease (3, 4) . Prescription medications are critical to the effective management of respiratory disease, which is reflected in increased spending. However, rising healthcare costs are passed on to patients through higher OOP expenses, resulting in one-quarter of families reporting a significant financial burden (5). This burden is greatest among individuals with low and middle incomes who have a chronic condition, with OOP spending doubling between zero and one condition and between two and multiple conditions (6) . Higher OOP medication costs impose a financial burden on families that is known to increase stress and fear and to induce cost-related nonadherence-an adaption that affects nearly one-third of adults with chronic conditions, worsens health status, and leads to unnecessary hospitalizations (7) (8) (9) . Among economically developed countries, cost-related nonadherence is highest in the United States (10) . Cost-saving tactics include taking smaller doses, skipping doses, delaying refills, and borrowing medicines from others (11) . Transferring medication costs from third-party payers to patients may burden patients without yielding corresponding savings if nonadherence leads to increased healthcare utilization in other service settings (e.g., hospital admissions).
The high cost of prescription medications coincides with increases in all forms of healthcare spending (12) . Although health spending is highest in the United States, all economically developed nations struggle to ensure their health expenditures are fiscally sustainable (12) . Other economically developed countries have taken greater steps than the United States to use national policies to curb health spending and protect patients from OOP expenses. Because these mechanisms rely heavily on government regulation, negotiation, and price setting, they have gained little favor in the United States.
Pharmaceutical policy in the United States is not hampered by a lack of expert recommendations (13-15) but rather by lack of political will to act on them on a scale that could benefit the nation as a whole. For example, the National Academies of Science, Engineering, and Medicine recently outlined a series of evidence-based recommendations to improve medication affordability (16) . Although the task force provided actionable guidance to federal agencies who have legal authority to implement specific recommendations, two factors act to reinforce the status quo: 1) the approach for reform remains fragmented, and 2) the pharmaceutical market is an evolving and complex endeavor for which continued and careful examination of evidence is needed to evaluate the success (and failure) of policy recommendations.
More coherent and consistent pharmaceutical policies are needed at the national level to ensure Americans have equitable access to affordable prescription medications. The American Thoracic Society (ATS) supports policies that give people the best available resources to manage their health, including affordable access to pharmaceutical therapies, while also supporting innovation in the development of new efficacious treatments. To meet these challenges, this ATS policy statement recommends the establishment of a publicly funded, politically independent, AMERICAN THORACIC SOCIETY DOCUMENTS impartial entity to systematically draft evidence-based pharmaceutical policy recommendations at the national level. This statement outlines key features of the pharmaceutical supply chain that impact people with chronic respiratory conditions, highlights international examples of how those features can be better managed, and concludes with our rationale of how such an entity can be integrated into our unique political system to provide impactful regulatory guidance.
Methods
A multidisciplinary expert committee developed this policy statement. A full working group was recruited at the initiation of the project, comprising experts in health policy, pharmaceutical policy and pharmacoeconomics, behavioral and translational science, pediatric and adult respiratory medicine, industry, and patients. Conflicts of interest were vetted and managed according to the policies and procedures of the ATS. This policy statement was developed through an iterative, consensusbased process that included face-to-face meetings, electronic polls and correspondence, and teleconferences. The full committee participated in topic-focused writing committees and provided expertise on various sections of the statement. A writing committee consisting of the co-chairs drafted the initial policy statement. The statement was reviewed by the full committee on multiple occasions and ultimately approved by the ATS Board of Directors.
The Pharmaceutical Supply Chain in the United States
The current market for prescription medications is complex and contains numerous government and private entities that regulate, develop, distribute, dispense, and purchase prescription medications. Recommendations addressing affordable access to pharmaceutical therapies must acknowledge the diverse roles that these entities play in making medications available to patients. We highlight the contributions of and structural challenges facing manufacturers, distributers, insurers, and prescribers as they seek to control growing pharmaceutical costs for patients with chronic lung disease.
Manufacturers and Patent Laws
Pharmaceutical manufacturers engage in drug research, development, evaluation, licensing, and marketing, with the aim of distributing therapies for a range of diseases. Pharmaceutical manufacturers are an important entity ensuring that innovative therapies are made available to the public. Although physician marketing and directto-consumer advertising are often a focus of scrutiny when it comes to examining costs, one of the most costly investments made by manufacturers includes the complex clinical trials required to evaluate efficacy, inform safety, and meet regulatory requirements (16) .
A number of legal protections, including regulatory and patent-related exclusivity, prolong the life span of branded therapies, allowing patient cost of medications to be influenced by the wholesale price set by manufactures (14) . Although patent exclusivity is intended to reward novel drug development, it can also protect profits at the expense of lower prices for respiratory medicines, particularly those delivered by inhalation. For example, the U.S. Food and Drug Administration (FDA) banned the production and sale of all chlorofluorocarbon (CFC)-based albuterol inhalers in 2008 in response to an international agreement to reduce environmental contaminants that were depleting the ozone layer. As an unintended consequence, generic CFC inhalers were replaced by more expensive, patented hydrofluoroalkane inhalers, prompting higher OOP costs for patients, especially those privately insured (17) . At this time, there are still no marketed generic albuterol inhalers. In addition to this unusual circumstance, respiratory medicines delivered by inhalation are more protected from generic competition than orally ingested medications because of the complexity of patent law involved in proprietary pump designs, delivery systems, formulations, and production processes that hinder generic competition when the active ingredient may no longer be patent protected. Oversight provided by a patientoriented, politically independent entity could help detect and mitigate unintended consequences of regulatory actions that sustain high prescription medication prices.
Distribution Channels and Insurers
Prescription medications are made available to patients only after passing through several intermediaries. Most recently, Pharmacy Benefit Managers (PBMs) have become influential intermediaries that secure prescription medications from manufacturers on behalf of health plans and employers. Although pharmacies often provide patients with direct access to prescription medications, PBMs exist behind the scenes to develop and maintain formularies, sell medications and provide rebates to pharmacies, negotiate discounts and obtain medications from drug manufacturers, and process prescription drug claims on behalf of insurers. Three large PBMs serve 75% of the U.S. market (14) . Although there is some consistency for public payers, like Medicaid, prices paid by private insurers are highly variable and typically lack price transparency. As a result, the prices paid insurers, pharmacies, and individual patients vary widely (18) . Numerous intermediaries exist between manufacturers and patients; accordingly, each step in the supply chain is associated with mark-ups, such that $1 out of every $5 spent on prescription drugs feeds profits in the distribution system (19) . In Europe, the price that such suppliers can charge is limited to a fixed percentage cost of the medication being supplied.
Many insurance policies impose substantial cost-sharing requirements that impact OOP prescription drug spending, including general medical deductibles, copayments, and coinsurance. These requirements vary depending on whether the health insurance is publically or privately sponsored. For instance, high-deductible private plans often require thousands of dollars in spending before subsidizing prescription medication costs. Alternatively, public plans, like Medicare, tend to impose smaller deductibles but lack an annual expenditure cap, exposing some beneficiaries (e.g., those undergoing cancer chemotherapy) to high OOP spending owing to coinsurance payments above the Medicare Part D catastrophic spending threshold. More routinely, Medicare patients with common chronic respiratory diseases like chronic obstructive pulmonary disease (COPD) may pay up to $1,200 annually to cover singlemaintenance inhaler treatment, a striking 79% of the total drug cost (20) . Until the "donut hole" is phased out, those who use more than two inhalers will almost certainly reach this coverage gap where they are responsible for up to one-third of the drug costs until the catastrophic limit is reached, at which point they are responsible for 5%. By federal regulation, Medicare patients AMERICAN THORACIC SOCIETY DOCUMENTS cannot receive any copayment assistance from the pharmaceutical company marketing the product.
Prescribers
Pharmaceutical company relationships with physicians have long been scrutinized for their impact on prescribing more expensive, branded medicines (21) . Over the last decade, many policies have been enacted to reduce product detailing (22) in an attempt to reduce branded prescribing when generic alternatives are available (23) . An unintended consequence is the deceleration of the adoption of new therapies (24) . This is especially concerning for novel therapies for patients with rare diseases, where delayed uptake could deprive these patients of clinically beneficial therapies.
Over time, more prescribers have come to recognize that treatment costs can impact adherence with treatment recommendations and/or place undue financial burden on patients (25, 26) . For many lung diseases, such as asthma and COPD, few suitable generics are available. Prescribing branded medications in these circumstances forces patients to pay more, because these medications are typically placed in higher formulary tiers with larger copayments. Thus, prescribers are placed in a catch-22, where prescribing efficacious treatments may not offer the expected benefits owing to greater nonadherence as a result of cost.
Prescribers often lack adequate information or training to prescribe in a costconscious manner to improve affordability. Given large heterogeneity between health insurance formularies, costs for the same treatments are highly variable between patients. Formularies change frequently, making it even more challenging for prescribers to address affordability for individual patients. Because hospitals have unique formularies, patients may be prescribed one type of medication before hospitalization, given a different one during the hospitalization, and then be prescribed that inhaler at discharge-meaning patients may, at times, be purchasing duplicative medications.
Pharmaceutical Supply Chain in the International Context
In an effort to ensure the safety, availability, and access to health-promoting pharmaceutical products worldwide, the World Health Organization released evidence-based guidelines to assist national policy makers and other stakeholders to manage pharmaceutical prices (27) . Recommendations included greater regulation of mark-ups in the pharmaceutical supply chain, tax exemptions for pharmaceutical products, use of external reference pricing, promotion of generic medicines, and greater use of health technology assessments (27) . These recommendations are widely used by high-income countries, but not the United States.
Outside of the United States, the European Union (EU) comprises the second largest concentration of pharmaceutical industries and suppliers of patented medications. For more than two decades, EU countries have been focusing on containing pharmaceutical expenditures and ensuring affordable access to medicines (28) . Although prescription medication prices are higher in the United States than any other advanced nation, prices in the EU have been increasing (29) for many years as well (14) . Several features of EU countries help explain their lower prices. In general, the EU has a greater commitment to fulfill a right to health care and essential medicines for its citizens (28) . They also work to ensure that health policies in member nations do not disrupt the goals and operation of the internal EU market-a larger EU objective (28) . Thus, EU pricing reflects that overarching goal. Although individual countries have some leeway in price setting, all member nations must comply with EU provisions governing transparency, regulation, and approval. One common approach for individual EU countries is to use external reference pricing-that is, setting their prices on the basis of comparison prices in other member nations, often adopting the lowest price. Canada has also adopted reference pricing using EU member nations as common comparators. The European Commission, an elected group represented by each member country that maintains the general interests of the EU and can propose legislation, has been examining many of the same issues that face the United States in pharmaceutical policy reform. Examples of these issues include adequate generic supply and the pharmaceutical lobby.
Many countries with universal health care and/or multipayer systems have national organizations responsible for conducting health technology assessments that generate evidence to support reimbursement decisions and price setting, including Australia, Canada, Germany, Ireland, and the United Kingdom. Organizations adopt a range of review criteria, including clinical, comparative, and cost-effectiveness evidence to drive decision making. In the United States, these same approaches have been undertaken by nongovernmental organizations, such as the Institute for Clinical and Economic Review and individual physician and patient advocacy groups; however, these efforts are isolated and underfunded, and their work is not widely used in practice.
Recommendations
Recommendation 1: The U.S. government should establish and financially support a politically independent, impartial expert advisory committee tasked with making evidence-based recommendations on pharmaceutical policy. Their overarching goal would be to ensure affordable access to life-preserving medications while retaining consumer choice, promoting future innovation, and respecting our market-based economy.
Without a single entity to coordinate and/or regulate the activities of the various parties comprising the pharmaceutical supply chain in the United States, broad adoption of evidence-based policies has fallen behind that of other economically developed nations. Accordingly, patients are unduly burdened by high treatment costs and, as a result, experience greater morbidity due to cost-related nonadherence. Over the past decade, numerous entities have proposed policies to curb the rise in prescription medication prices, including encouraging greater price transparency, changing patent law, and adopting value-based purchasing (16) . However, lacking any clear standing, these recommendations have been largely ignored. The National Academies of Science, Engineering, and Medicine recently recommended numerous targeted, evidence-based reforms based on the best available evidence to address inefficiencies in the pharmaceutical supply chain (16) .
Although our committee is supportive of many of these recommendations, we intentionally refrained from championing any particular strategy, owing to our belief that adopting highly targeted policies in a piecemeal fashion will not sufficiently address the long-term challenges posed by a complex, ever-evolving system (16) .
Instead, the problem calls for a permanent entity with sufficient standing to confront entrenched stakeholders and adapt to changing circumstances. To address this long-term need, we unanimously recommend that the U.S. government establish and financially support an independent expert advisory committee tasked with making recommendations on pharmaceutical policy. The fact that 75% of Americans already favor the creation of an independent group with specific focus on the costs of prescription medicines lends credence to the acceptability of our recommendation (30) .
Given the magnitude of the challenge, only the federal government is positioned to facilitate, fund, and organize this effort. However, public distrust in government and hyper-partisanship would invariably threaten the impartiality of such an entity without a high degree of independence from political forces. Therefore, we propose the creation of an independent entity for pharmaceutical reform be modeled after the successful example of the U.S. Preventive Services Task Force (USPSTF). This entity, supported by the Agency for Healthcare Research and Quality, has served in an independent, impartial advisory capacity since 1984 (31) .
The example of the USPSTF demonstrates how the federal government can effectively advance health policy formulation independent of partisan influence. The USPSTF comprises an independent group of national experts in prevention and evidence-based medicine that works to improve the health of all Americans by making evidence-based recommendations about clinical preventive services. Because its recommendations are not subject to government approval, they are highly respected by the general public, public officials, healthcare entities, and clinicians. A notable example of how the USPSTF has exerted tangible impact on national health policy is reflected by the Affordable Care Act requirement that all public and private insurers must provide recommended preventive services without patient cost sharing. Admittedly, this provision only had incremental impact on our health system, but, as recently pointed out, "incremental change is not necessarily inconsequential change" (32) .
Other similar organizations exist that operate independently to support evidencebased practice and policy, and their operating procedures could be considered as models for the proposed entity, including the Medicare Payment Advisory Commission and the Congressional Budget Office.
Structure of an independent expert advisory committee. An independent, expert advisory committee would be composed of national pharmaceutical policy experts representing a broad range of stakeholders, including clinicians, pharmacists, researchers, public health practitioners, patient advocates, industry and legal experts, and economists. Like the USPSTF, individuals would be publicly nominated. Members would be appointed to serve fixed terms and screened to ensure that they have no substantial conflicts of interest that could impair the scientific integrity of the entity's work. Similar to the Medicare Payment Advisory Commission, members would ultimately be confirmed by the Comptroller General. A clear set of conflictof-interest protocols would be established to monitor and manage conflicts.
The newly proposed entity would be tasked with making evidence-based recommendations regarding the myriad of factors that influence access to affordable prescription medications. Their overarching goals would be to make recommendations that, if implemented, would likely result in improved access to life-preserving medications, while retaining consumer choice, promoting future innovation, and respecting our market-based economy. The entity would require an appropriate infrastructure to conduct evidence reviews. They would necessarily seek feedback from professional societies, advocacy groups, and expert consultants as needed. This would provide an important avenue for ATS to shape important policy recommendations that impact patient affordability of respiratory therapies. Recommendations would contain detailed information about the primary evidence behind it and how to implement the recommendation. Like the USPSTF, when there is not enough evidence to support a recommendation, the entity would make a clear call for needed research. The entity would have at least two annual required reports to the U.S. Congress, who, along with government agencies with legislative authority, would ultimately enforce and implement recommendations. Reports would make clear recommendations to government agencies (e.g., the FDA) with definitive legislative authority or to the U.S. Congress to grant legislative authority where necessary (16) . This paper, the National Academies of Science, Engineering, and Medicine report on making medicines more affordable (16) , and others (14, 15) have identified several key areas for further examination to inform evidence-based pharmaceutical policy reform that this new entity can draw from to initiate their scope of work, including value-based pricing, transparency, and uniform negotiation. Table 1 highlights priorities in pharmaceutical policy reform in the United States to support the ATS mission and patient affordability and access.
Recommendation 2: An immediate priority of the aforementioned committee is to examine the evidence and make recommendations to reduce barriers to timely generic drug availability.
A critical issue for patients with respiratory disease is the high out-of-pocket costs of inhalers owing to lack of low-cost generic availability and variation in coverage on insurance formularies. Advair, for example, a commonly prescribed medicine for asthma and COPD, had its U.S. patent expire in 2010, but a generic version has yet to enter the market at the time of this writing. As previously mentioned, generic availability of albuterol has also faced challenges. If the proposed entity had been around at the time generic CFC inhalers were replaced by patented hydrofluoroalkane inhalers, they would have been equipped to anticipate the lack of availability of albuterol generics as a result of the change and the anticipated cost consequences. Their work could have therefore addressed the issue and perhaps avoided the untenable situation we are in now.
Entry of generic medicines into the market has historically shown that the price of previously patented medicines can drop substantially as a result of increased competition among manufacturers. However, delays in generic entry of AMERICAN THORACIC SOCIETY DOCUMENTS medicines and the rising costs of generics in general because of fewer suppliers have created a situation that requires intervention. Key issues that an established entity would provide evidence review and recommendations on would include industry practices to extend patent exclusivity, FDA backlogs of safe generic entry onto the market, and increasing availability of manufactures and their ability to compete (16) . Despite the established clinical benefit of both albuterol and combination inhaled corticosteroids plus long-acting b-agonists in mitigating respiratory symptoms and exacerbations, these therapies are not guaranteed on Tier 1 formularies of all insurance plans where out-of-pocket costs would be the lowest for patients compared with other tiers. Although the Affordable Care Act established an essential benefits list that includes prescriptions, there are not specific protections for certain medicines or specific guidance or incentives around formulary tiering. A reexamination of essential prescription lists is needed, with more uniformity in how insurance plans cover medicines from each drug class at minimal cost to patients.
Conclusions
The ATS supports policies that improve the health and well-being of patients with chronic lung disease. At present, pharmaceutical costs of common therapies are burdensome for many patients and a major barrier to medication adherence. As other countries have demonstrated, this burden can be mitigated. We recommend the federal government establish and fund an independent, impartial entity to spearhead U.S. pharmaceutical policy reform and prioritize the availability of low-cost generic medicines with proven clinical benefit, having essential medicines from each drug class on all Tier 1 formularies. This entity would shape pharmaceutical policy reform by developing evidence-based policies that are congruent with international best practices yet consistent with our unique national values. We believe that an independent, impartial entity dedicated to tackling the complex issues involving the development, manufacture, distribution, and sale of pharmaceutical products would be best positioned to improve our patients' access to affordable, life-preserving, and lifeenhancing therapies long term. Such an entity represents a best first step for incremental, yet meaningful, reform of U.S. pharmaceutical policy. n (14, 16) Expand flexibility of formulary design to mitigate cost burdens to patients.
Essential respiratory medicines with established clinical benefit should be available in Tier 1 formularies.
Reduce barriers to timely generic drug availability and foster competition to ensure continued affordability.
Promote expeditious market entry of international providers of generic and novel medicines.
Establish uniform and meaningful negotiation with producers and suppliers of medicines in the pharmaceutical supply chain.
Establish price transparency of financial flows through the pharmaceutical supply chain.
Establish a cost-effectiveness research agenda and action plan that develops value metrics for therapies and a uniform pharmaceutical value framework.
Expand value-based pricing and benefit design, including demonstration projects to test alternative payment models on outcomes and costs.
Incentivize development of truly new medicines.
Ensure that financial incentives for the prevention and treatment of rare diseases are not extended to widely sold drugs.
Expand stock albuterol programs in schools within all 50 states.
Establish an infrastructure for ongoing examination of patient affordability and availability and access to assistance programs.
Define a list of essential medicines and routinely examine this list.
Establish policies to reduce academic detailing, lobbying, direct-to-consumer drug advertising, and anticompetitive deals.
Compare expenses and processes of early-stage drug development research between NIH, small industry, and large pharmaceutical manufacturers.
Modify requirements for the award and extension of exclusivity rights.
AMERICAN THORACIC SOCIETY DOCUMENTS

